DexCom Reports Mixed Q4 Results, Stock Rises 7.8%

DexCom Inc. reported mixed results for its Q4 2024 earnings, with revenues slightly exceeding expectations at $1.114 billion, marking an 8% year-over-year growth, driven largely by international expansion. However, earnings per share (EPS) fell short of forecasts, coming in at $0.45 compared to an anticipated $0.50, reflecting challenges in profit conversion and operational costs. The company's shares have increased by 7.8% since the start of the year despite these mixed results. Revenue projections for 2025 remain unchanged at $4.61 billion, with analysts maintaining a price target of $100, indicating confidence in the company's strategic direction. DexCom's continuous glucose monitoring systems, including the G7 and the newly launched Stelo, continue to drive its market presence. The company faces competition from similar products like Abbott's Lingo but is focusing on regulatory approvals and market expansions to sustain growth.